Below, we highlight the earnings lineup for the week ahead:
A Big Week For Big BanksInvestors should keep a close eye on financials and banking ETFs as several bellwethers post their second quarter results:
Charles Schwab (SCHW): On Tuesday, this investment bank is expected to post earnings at $0.19 per share and quarterly revenues at $1.3 billion.
Goldman Sachs Group (GS): This bellwether is expected to report an EPS of $2.82, down from the previous quarter�� $4.29 reading. Revenues are also forecasted to come in lower at $8.0 billion.U.S. Bancorp (USB): EPS for this regional bank is estimated to rise to $0.76 from the previous $0.73 EPS recording. The company reports on Wednesday.The PNC Financial Services Group, Inc. (PNC): Another regional bank, PNC is expected to post earnings at $1.62 per share and revenues at $3.9 billion on Wednesday.Bank of America Corp (BAC): EPS estimates for this bellwether are around $0.26, slightly higher than the previous two quarters��$0.21 reading. Revenues are expected to dip slightly to $22.8 billion .American Express Co (AXP): On Wednesday, this credit card giant is expected to post earnings at $1.22 per share and revenues at $8.3 billion.Morgan Stanley (MS): This investment bank will report on Thursday; estimates for EPS are around $0.45 while revenues are expected to fall slightly to $7.9 billion.BB&T Corp. (BBT): This regional bank is expected to report EPS at $0.74 and revenues at $2.5 billion.Tech Reports On TapA number of tech giants will also be reporting thi! s week; investors should keep close watch on�Technology Equities�and�Communications Equities�ETFs:
Top 10 Cheap Stocks To Buy Right Now: LM Ericsson Telephone Company(ERIC)
LM Ericsson Telephone Company provides communications equipment, professional services, and multimedia solutions to mobile and fixed networks operators worldwide. The Networks segment delivers radio access solutions that interconnect with devices, such as mobile phones, notebooks, and PCs; fixed access solutions for fiber and copper; and IP core network solutions, including softswitches, IP infrastructure for edge- and core routing, IP multimedia subsystem, and media gateways. This segment also offers transmission/backhaul; and microwave and optical transmission solutions for mobile and fixed networks, as well as offers network management tools for configuration, performance monitoring, security management, inventory management, and software upgrades. The Global Services segment delivers managed services comprising network design and planning, network operations, field operations and site maintenance, and shared solutions, as well as consulting and systems integration, cus tomer support, and network rollout services. The Multimedia segment provides IPTV solutions, video compression, on-demand solutions, content management systems, advertising, and interactive TV applications for operators, service providers, advertisers, and content providers; and business support systems, including revenue management, customer care, provisioning, device management, and analytics. This segment also offers service delivery platforms, communication suite, messaging, social media portal, and location-based services for consumers; and business communication solutions, such as business communication suite and brokering solutions that facilitate payment and distribution of content. The Sony Ericsson segment offers mobile phones, accessories, content, and applications. The ST-Ericsson segment develops and sells semiconductors and wireless platforms to handset manufacturers, mobile operators, and device manufacturers. The company was founded in 1876 and is headquarter ed in Stockholm, Sweden.
Advisors' Opinion:- [By Michael A. Robinson]
IMS Research says there will be 30 billion connected devices by 2020. Telefonaktiebolaget LM Ericsson (Nasdaq ADR: ERIC)- one of the largest telecommunications companies on the planet - says there will be 50 billion enabled devices in place worldwide in that same time frame.
Top 5 Regional Bank Companies To Own In Right Now: Arch Coal Inc. (ACI)
Arch Coal, Inc. produces and sells thermal and metallurgical coal from surface and underground mines located in the United States. As of December 31, 2013, it operated or contracted out the operation of 22 mines, and owned or controlled approximately 5.3 billion tons of proven and probable recoverable reserves. The company also owned or controlled primarily through long-term leases approximately 32,135 acres of coal land in Ohio; 22,417 acres of coal land in Maryland; 46,532 acres of coal land in Virginia; 425,038 acres of coal land in West Virginia; 107,668 acres of coal land in Wyoming; 267,024 acres of coal land in Illinois; 19,428 acres of coal land in Montana; 21,802 acres of coal land in New Mexico; and 20,166 acres of coal land in Colorado, as well as coal land in Kentucky. In addition, it owned or controlled through long-term leases smaller parcels of property in Alabama, Indiana, Washington, Arkansas, California, Utah, and Texas. The company sells coal to power pl ants, steel mills, and industrial facilities. Arch Coal, Inc. was founded in 1969 and is headquartered in St. Louis, Missouri.
Advisors' Opinion:- [By Aimee Duffy]
The great majority of this country's coal production comes from Wyoming's Powder River Basin. The two leading producers there, Peabody Energy (NYSE: BTU ) and Arch Coal (NYSE: ACI ) , account for more than half the production in the entire basin, producing 139 million tons and 100 million tons, respectively, in 2012. But as coal demand in this country shrinks, Peabody and Arch have pinned their hopes on exports. Unfortunately, what these companies are finding is that exporting coal from ports on the Pacific coast is an increasingly contentious business.
- [By Ben Levisohn]
Among thermal-oriented names, we suggest [Consol Energy] and [Arch Coal (ACI)], while Peabody and Alpha should benefit from global economic recovery trends. We expect the group to benefit from potential natural gas pricing improvements and investors positioning for cyclical exposure during 2014.
- [By Matt Thalman]
Matt discusses Peabody (NYSE: BTU ) , CONSOL Energy (NYSE: CNX ) , Arch Coal (NYSE: ACI ) , and Alpha Natural Resources (NYSE: ANR ) , which one he likes best, and why he would stay away from the other three.
- [By Robert Rapier]
For years the coal industry has suggested that carbon capture and storage technologies would come along to save the day. But this year the Norwegian government abandoned support for a project that was supposed to demonstrate carbon capture and storage on commercial scale. Thus, coal in the US appears to be on the way out.
US coal producers have been battered as a result. Leading suppliers Peabody Energy (NYSE: BTU) and Arch Coal (NYSE: ACI) saw their share prices decline by another 30 percent and 40 percent, respectively, in 2013. This was on top of steep declines in 2011 and 2012, so that the total market capitalization of BTU and ACI has declined by 71 percent and 87 percent over the last three years.
No country in the world has decreased coal consumption as much in recent years as has the US. This explains the declining fortunes of coal companies with significant operations in the US. But no country has increased coal consumption as much as China. In fact, were it not for China, global consumption of coal would have decreased over the past five years. Instead, the world continues to set new records for coal consumption.
Top 5 Regional Bank Companies To Own In Right Now: Inovio Pharmaceuticals Inc (INO)
Inovio Pharmaceuticals, Inc., incorporated on June 29, 1983, is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases. The Company's SynCon technology enables the design of universal vaccines capable of providing cross-protection against existing or changing strains of pathogens, such as influenza and human immunodeficiency virus (HIV). The Company's electroporation delivery technology uses brief, controlled electrical pulses to increase cellular uptake of the vaccine. Its clinical programs include cervical dysplasia (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus (HCV) and HIV vaccines. It is advancing preclinical research and clinical development for a universal seasonal/pandemic influenza vaccine, as well as preclinical work for other products, including malaria and prostate cancer vaccines. Its partners and collaborators include University of Pennsylvania, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, Program for Appropriate Technology in Health/Malaria Vaccine Initiative (PATH/MVI), National Institute of Allergy and Infectious Diseases (NIAID), Merck, ChronTech, University of Southampton, United States Military HIV Research Program (USMHRP), the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and HIV Vaccines Trial Network (HVTN). As of December 31, 2011 it owned 16.1% interest in VGX Int��.
Inovio�� Solution
The Company�� synthetic vaccine platform consists of its SynCon vaccine design process and electroporation delivery technology. It has developed a preclinical and clinical stage pipeline of vaccines. The Company�� synthetic vaccines are designed to prevent a disease (prophylactic vaccines) or treat an existing disease (therapeutic vaccines). Its synthetic vaccine consists of a deoxyribonucleic acid (DNA) plasmid encoding a selected antigen! (s), which is introduced into cells of humans or animals with the purpose of evoking an immune response to the encoded antigen. The Company�� synthetic vaccines are designed to generate specific antibody and/or T-cell responses.
The Company�� SynCon technology provides processes that employ bioinformatics, which combine extensive genetic data and sophisticated algorithms. Its design process uses the genetic make-up of a common antigen(s) from multiple strains of a virus within a viral sub-type or taxonomic group (family) of pathogens, such as HIV, hepatitis C virus (HCV), human papillomavirus (HPV), influenza and other diseases to synthetically create a new antigen for the desired pathogen target that does not exist in nature. Its synthetic vaccine candidates are being delivered into cells of the body using its electroporation (EP) DNA delivery technology.
Cancer Synthetic Vaccines
The Company has two broad types of cancer vaccines: preventive (or prophylactic) vaccines, which are intended to prevent cancer from developing in healthy people, and treatment (or therapeutic) vaccines, which are intended to treat an existing cancer by strengthening the body�� natural defenses against the cancer. Two types of cancer preventive vaccines are available in the United States. The United States Food and Drug Administration (the FDA) has approved two vaccines, Gardasil and Cervarix that protect against infection by the two types of HPV-types 16 and 18-that cause approximately 70% of all cases of cervical cancer worldwide. In addition, Gardasil protects against infection by two additional HPV types, 6 and 11, which are responsible for about 90% of all cases of genital warts in males and females but do not cause cervical cancer.
Cervarix manufactured by GlaxoSmithKline, is composed of virus-like particles (VLPs) made with proteins from HPV types 16 and 18. Cervarix is approved for use in females��ages 10 to 25 for the prevention of cervical cancer caused by! HPV type! s 16 and 18. Gardasil manufactured by Merck, is approved for use in females for the prevention of cervical cancer, and some vulvar and vaginal cancers, caused by HPV types 16 and 18 and for use in males and females for the prevention of genital warts caused by HPV types 6 and 11. The vaccine is approved for these uses in females and males ages 9 to 26. The FDA has also approved a cancer preventive vaccine that protects against hepatitis B virus (HBV) infection.
Inovio�� VGX-3100 is designed to raise immune responses against the E6 and E7 genes of HPV types 16 and 18 that are present in both pre-cancerous and cancerous cells transformed by these HPV types. E6 and E7 are oncogenes that play an integral role in transforming HPV-infected cells into cancerous cells. In March 2011, it initiated a randomized, double-blind Phase II study of VGX-3100 delivered using the CELLECTRA intramuscular electroporation device in women with HPV Type 16 or 18 and diagnosed with, but not yet treated for, cervical intraepithelial neoplasia (CIN) 2/3. The study is designed to enroll 148 subjects. In January 2011, it announced the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of its SynCon vaccine for prostate cancer targeting two antigens, prostate specific antigen (PSA) and prostate specific membrane antigen (PSMA).
In January 2011, the Company announced the regulatory approval of a Phase II clinical trial (WIN Trial) to treat leukemia utilizing its new ELGEN 1000 automated vaccine delivery device. The single dose level, Phase II study, called WT1 immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation. Cancer Vaccines encodes for hTERT, an antigen related to non-small cell lung, breast and prostate cancers. The vaccine is delivered using its electroporation delivery technology.
Infectious Disease Synthetic Vaccines
In Marc! h 2011, the Company announced the initiation of a follow-on open label, single dose Phase II clinical study in collaboration with ChronTech of the ChronVac-C HCV DNA vaccine delivered using its electroporation technology in treatment naive HCV infected individuals. Its HIV vaccines consist of candidates for HIV prevention, as well as therapy or treatment. PENNVAX-B is designed to target HIV clade B (most commonly found in the United States, North America, Australia and the European Union (EU). PENNVAX-G is designed to target HIV clades A, C and D, which are more commonly found in Asia, Africa, Russia and South America. This Phase I clinical study of PENNVAX-B (HVTN-080) vaccinated 48 healthy, HIV-negative volunteers to assess safety and levels of immune responses generated by Inovio�� PENNVAX-B vaccine delivered with its CELLECTRA electroporation device. PENNVAX-B is a SynCon vaccine that targets HIV gag, pol, and env proteins.The Company�� VGX-3400X targets H5N1. The vaccine consists of three distinct DNA plasmids coded for a consensus hemagglutinin (HA) antigen derived from different H5N1 virus strains; a consensus neuraminidase (NA) antigen derived from different N1 sequences; and a consensus nucleoprotein (NP) fused to a small portion of the m2 protein (m2E) based on a broader cross-section of influenza viruses in addition to H5N1 and H1N1. Conventional vaccines are strain-specific and have limited ability to protect against genetic shifts in the influenza strains they target. They are therefore modified annually in anticipation of the next flu season�� new strain(s). It is focused on developing DNA-based influenza vaccines able to provide broad protection against known as well as newly emerging, unknown seasonal and pandemic influenza strains.
Animal Health/Veterinary
VGX Animal Health, Inc. (VGX AH), a majority-owned subsidiary, has licensed LifeTide, a plasmid-based growth hormone releasing hormone (GHRH) technology for swine. LifeTide is one of onl! y four DN! A-based treatments approved for use in animals and is the only DNA-based agent delivered using electroporation that has been granted marketing approval (Australia). VGX AH is also developing a GHRH-based treatment for cancer and anemia in dogs and cats. It is developing a synthetic vaccine for foot-and-mouth disease (FMD) administered by its vaccine delivery technology. The FMD virus is one of the most infectious diseases affecting farm animals, including cattle, swine, sheep and goats, and is a serious threat to global food safety.
The Company competes with Crucell N.V, Sanofi-Aventis, Novartis, Inc., GlaxoSmithKline plc, Merck, Pfizer, AstraZeneca, Inc., Novartis, Inc., MedImmune and CSL.
Advisors' Opinion:- [By Sean Williams]
No fairytale ending
Fairytale endings work great in the movies, but you rarely see them come to fruition in the real world. Small-cap biopharmaceutical Inovio Pharmaceuticals (NYSEMKT: INO ) has seen shares nearly triple since April on the heels of multiple intriguing studies, but will the glass slipper fit over the long term? - [By Roberto Pedone]
Another biotechnology player that insiders are jumping into here is Inovio Pharmaceuticals (INO), which discovers, develops, and develops synthetic vaccines and immune therapies focusing on cancers and infectious diseases. Insiders are buying this stock into notable weakness, since shares are off by 17.4% so far in 2014.
Inovio Pharmaceuticals has a market cap of $578 million and an enterprise value of $415 million. This stock trades at a premium valuation, with a price-to-sales of 30.15 and a price-to-book of 4.30. Its estimated growth rate for this year is 56.9%, and for next year it's pegged at -43.5%. This is a cash-rich company, since the total cash position on its balance sheet is $108.86 million and its total debt is zero.
The CEO just bought 250,000 shares, or about $2.26 million worth of stock, at $9.05 per share.
From a technical perspective, INO is currently trending below both its 50-day and 200-day moving averages, which is bearish. This stock has been downtrending badly for the last few weeks, with shares moving lower from its high of $14.20 to its recent low of $8.60 a share. During that downtrend, shares of INO have been consistently making lower highs and lower lows, which is bearish technical price action. Shares of INO have now started to explode higher off that $8.60 low and it's quickly approaching a big breakout trade.
If you're in the bull camp on INO, then I would look for long-biased trades as long as this stock is trending above Wednesday's intraday low of $8.92 or above that recent low of $8.60 and then once it breaks out above both its 50-day at $10.11 and its 200-day at $10.24 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 1.87 million shares. If that breakout hits soon, then INO will set up to re-test or possibly take out its next major overhead resistance levels at $11 to $11.50, or even $12 to $12.5
- [By Sean Williams]
On the clinical data front, Alnylam Pharmaceuticals (NASDAQ: ALNY ) and Inovio Pharmaceuticals (NYSEMKT: INO ) both put investors in their happy place.
- [By Jake L'Ecuyer]
Equities Trading DOWN
Shares of Inovio Pharmaceuticals (NYSE: INO) were down on Friday's session, falling 13.28 percent to $2.488 despite seemingly little news on the company.
Top 5 Regional Bank Companies To Own In Right Now: Eco Building Products Inc (ECOB)
ECO Building Products, Inc. (ECOB), incorporated on March 21, 2007, is a manufacturer of wood products treated with an eco-friendly chemistry that protects against fire, mold/mycotoxins, fungus, rot-decay, wood ingesting insects and termites with ECOB WoodSurfaceFilm and fire retardant coating). ECOB�� newest product, Eco Red Shield also serves as a fire inhibitor protecting lumber from fire, slowing ignition time and reducing the amount of smoke produced. The Eco Building Products line includes dimensional lumber, wall and floor panels, I-joists, GluLam Beams, laminated veneer lumber (LVL) beams, truss lumber and trim. These products can be coated at its production facilities and at the mill or distributor with its formula and coating machines. Its products include Eco Red Shield, Eco Clear Shield, Eco Blue Shield, Eco Shelter, Eco Cabinets, Smart Components Seismic Walls, Eco LVL Beam, Eco I Joist, Eco Corbels, Eco Trim, Eco LVL Studs, and Calvert Curved Beams.
As of June 30, 2012, the Company owned 100% of E Build & Truss, Inc. (E Build), Red Shield Lumber, Inc. (Red Shield) and Seattle Coffee Exchange (Seattle). Red Shield was formed for the purpose of opening a plant in Canada utilizing the Company�� red coating process for sale and distribution. As of December 31, 2011, the wholly owned subsidiary had little operating activity. E Build was formed for the purpose of operating the Company�� Framing Labor and Truss manufacturing activities. ECOB has developed a line of eco-friendly protective wood coatings that extend the life of framing lumber and other wood used in the construction of single-family homes, multi-story buildings, as well as The Eco Shelter. In December 2011, the Company formed Seattle in the State of California. Seattle is a coffee shop which is located in the 1st floor of the Company�� corporate headquarters in Vista, California. This wholly owned subsidiary has not started its operations, as of June 30, 2012.
The Company�� eco-friendly formula ! controls moisture and protects lumber from mold, mildew, fungus, decay, rot, termites (and other wood boring insects including Formosan termites), while simultaneously serving as a fire inhibitor. The Company�� eco-friendly formula was designed for staining - it controls moisture and protects lumber from mold, mildew, fungus, decay, rot, termites while simultaneously serving as a fire inhibitor. ECOB�� eco-friendly formula controls moisture and protects lumber from mold, mildew, fungus, decay, rot, termites (and other wood boring insects including Formosan termites). Eco Red Shield Smart ComponentsO wall systems are pre-engineered seismic wall systems. The Company�� pre-engineered and pre-packaged kit comes pre-cut and ready to assemble with hammer and nails - the simple design makes it ideal for rapid response relief housing, events, offices, meeting halls, storage sheds, medical clinics and more. It is available in a range of sizes and floor plans.
Eco has delivered cabinet solutions for kitchen, bath, garage and office space. Smart Components is made with Eco Red Shield Protected Lumber for builders in seismic hot spots, such as California, Mexico and Japan. The I beam joist is eco-friendly solution to large structural beams. Laminated Eco Trim is protected on all six sides and available in any protective coatings providing a nearly impenetrable barrier against moisture, mold and insects. It also offers an ultra-smooth surface for painting and a clean, finished look that builders and homeowners desire.
The Company competes with Arch Chemical and Osmose, Inc.
Advisors' Opinion:- [By Peter Graham]
Small cap green stocks Eco Depot Inc (OTCMKTS: ECDP), Eco Building Products Inc (OTCMKTS: ECOB) and Profire Energy, Inc (OTCBB: PFIE) has been getting some extra attention lately in various investment newsletters thanks to paid promotions or investor relation campaigns. Of course, there is nothing wrong with properly disclosed promotions and investor relations campaigns, but small cap green stocks tend to be extra volatile when compared with other stocks. So how in greenbacks will these three small cap green stocks produce for investors? Here is a quick reality check:
No comments:
Post a Comment